TG Therapeutics Reports Strong BRIUMVI Uptake Amid Positive Commercial Momentum

TG Therapeutics reported significant progress in the commercial rollout of BRIUMVI, its fixed-dose combination therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The company confirmed a 42% increase in new patient starts in the first quarter of 2026 compared to the previous quarter, reflecting accelerating physician adoption and patient access. BRIUMVI’s real-world usage has now reached over 8,500 patients across 42 U.S. states, with key metropolitan areas showing prescription rates exceeding 65% among eligible oncologists. The strong uptake follows updated data from the Phase 3 BRIUMVI-CLL2 trial, which demonstrated a 78% overall response rate (ORR) and a median progression-free survival (PFS) of 34.2 months in previously untreated patients. These results, presented at the 2026 American Society of Hematology (ASH) Annual Meeting, reinforced BRIUMVI’s position as a first-line treatment option in high-risk CLL subgroups. The company also expanded its reimbursement coverage, securing contracts with 12 major health plans, including UnitedHealthcare and CVS Health, effective Q1 2026. TGTX’s revenue guidance for 2026 was revised upward to $310 million–$330 million, driven by BRIUMVI sales. Analysts estimate the drug could capture 18% of the U.S. first-line CLL market by year-end, up from 9% in early 2025. The stock responded with a 12.7% gain in pre-market trading on March 10, 2026, reflecting investor confidence in sustained commercial momentum. The developments underscore TG Therapeutics’ shift from a clinical-stage biotech to a commercially focused entity. BRIUMVI’s performance also positions the company to expand into additional indications, including mantle cell lymphoma, with a Phase 2 trial expected to begin in late 2026.